Skip to content

奥鲁卡治疗

US · ORKA #2003 按市值排名 上市于 1970
71.93 -1.94 -2.63%
实时 - 追踪5344个代码 - 心跳于12秒前 · 2026-10-16 19:30

最新新闻

  • 评级变动
    Stifel Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $150
    \u5e02\u573a\u8d44\u8baf · 2026/6/29
  • UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $130
    \u5e02\u573a\u8d44\u8baf · 2026/9/2
  • 评级变动
    LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $125
    \u5e02\u573a\u8d44\u8baf · 2026/8/1
  • 评级变动
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Fractyl Health, Inc. (GUTS) and Oruka Therapeutics (ORKA)
    TipRanks · 2026/9/2
  • 评级变动
    Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), Alto Neuroscience, Inc. (ANRO) and Astrana Health (ASTH)
    TipRanks · 2026/7/14
  • 公司公告
    Kaishan Co., Ltd.: The holding company KS Orka Renewables Pte Ltd and PT Optima Nusantara Energi's announcement on joint development of the Simbolon-Samosir geothermal project
    SZSI · 2018/3/19
  • 公司公告
    Kaishan Co., Ltd.: Announcement on the signing of a letter of intent for a joint venture between its wholly-owned subsidiary KS ORKA and a Hungarian partner
    SZSI · 2025/11/27
  • 评级变动
    UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $100
    \u5e02\u573a\u8d44\u8baf · 2026/6/2
  • Wedbush Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $165
    \u5e02\u573a\u8d44\u8baf · 2026/9/24
  • Barclays Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $160
    \u5e02\u573a\u8d44\u8baf · 2026/9/21
  • 评级变动
    A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $151 to $200
    \u5e02\u573a\u8d44\u8baf · 2026/8/11
  • A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $120 to $175
    \u5e02\u573a\u8d44\u8baf · 2026/9/24
  • 评级变动
    LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $175
    \u5e02\u573a\u8d44\u8baf · 2026/9/9
  • 评级变动
    UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Raises Target Price to $130
    \u5e02\u573a\u8d44\u8baf · 2026/7/1
  • 评级变动
    Piper Sandler Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $180
    \u5e02\u573a\u8d44\u8baf · 2026/8/17
  • 公司公告
    Kaishan Co., Ltd.: Announcement on KS ORKA Hungary\'s acquisition of exclusive geothermal exploration rights in Hungary
    SZSI · 2025/4/10
  • 评级变动
    H.C. Wainwright Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $120
    \u5e02\u573a\u8d44\u8baf · 2026/9/3
  • 评级变动
    A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $133 to $180
    \u5e02\u573a\u8d44\u8baf · 2026/8/12
  • 评级变动
    TD Cowen Maintains Oruka Therapeutics(ORKA.US) With Buy Rating
    \u5e02\u573a\u8d44\u8baf · 2026/8/26
  • BTIG Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $151
    \u5e02\u573a\u8d44\u8baf · 2026/10/2

新闻标题为自动聚合内容,未经我们团队独立核实或编辑。

报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

奥鲁卡治疗 讨论区 0 条评论

发表评论